TRACON Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

TRACON PharmaceuticalsDie Umsatzerlöse des Unternehmens werden voraussichtlich um 121.7% pro Jahr zurückgehen, während die jährlichen Gewinne voraussichtlich um 8.8% pro Jahr wachsen werden. Der Gewinn pro Aktie wird voraussichtlich um 4.7% pro Jahr wachsen.

Wichtige Informationen

8.8%

Wachstumsrate der Gewinne

4.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.1%
Wachstumsrate der Einnahmen	-121.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	01 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

Gewinn- und Umsatzwachstumsprognosen

OTCPK:TCON - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-1	N/A	-3	1
12/31/2025	N/A	-2	N/A	-6	1
12/31/2024	0	-11	N/A	-15	1
3/31/2024	12	2	6	6	N/A
12/31/2023	12	-4	4	4	N/A
9/30/2023	9	-11	0	0	N/A
6/30/2023	9	-28	-22	-22	N/A
3/31/2023	N/A	-28	-25	-24	N/A
12/31/2022	N/A	-29	-26	-26	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-28	-28	N/A
3/31/2022	0	-33	-25	-24	N/A
12/31/2021	0	-29	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-22	-17	-17	N/A
3/31/2021	N/A	-18	-17	-17	N/A
12/31/2020	N/A	-17	-17	-17	N/A
9/30/2020	N/A	-16	-18	-18	N/A
6/30/2020	N/A	-18	-20	-20	N/A
3/31/2020	N/A	-19	-22	-22	N/A
12/31/2019	N/A	-23	-24	-24	N/A
9/30/2019	N/A	-26	-28	-28	N/A
6/30/2019	N/A	-30	-27	-27	N/A
3/31/2019	N/A	-34	-32	-32	N/A
12/31/2018	3	-35	-31	-31	N/A
9/30/2018	3	-34	-25	-25	N/A
6/30/2018	10	-24	-17	-17	N/A
3/31/2018	11	-20	-12	-12	N/A
12/31/2017	9	-19	N/A	-13	N/A
9/30/2017	9	-19	N/A	-17	N/A
6/30/2017	3	-26	N/A	-23	N/A
3/31/2017	3	-28	N/A	-28	N/A
12/31/2016	3	-27	N/A	-27	N/A
9/30/2016	4	-32	N/A	-29	N/A
6/30/2016	5	-32	N/A	-27	N/A
3/31/2016	8	-27	N/A	-21	N/A
12/31/2015	8	-24	N/A	-19	N/A
9/30/2015	8	-16	N/A	-15	N/A
6/30/2015	8	-12	N/A	-13	N/A
3/31/2015	4	-10	N/A	-11	N/A
12/31/2014	4	-7	N/A	2	N/A
9/30/2014	3	-7	N/A	3	N/A
6/30/2014	1	-7	N/A	3	N/A
3/31/2014	0	-8	N/A	3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TCONDas prognostizierte Gewinnwachstum (50% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: TCONDie Erträge des Unternehmens (8.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.7% pro Jahr).

Hohe Wachstumserträge: TCONDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: TCONDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-121.7% pro Jahr).

Hohe Wachstumseinnahmen: TCONDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-121.7% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TCON in 3 Jahren voraussichtlich hoch sein wird

TRACON Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to US$0.45 loss

Consensus revenue estimates increase by 50%

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

Recent updates

TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index

Investor sentiment improves as stock rises 16%

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.

TRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Tracon Pharmaceuticals, Inc. Announces Executive Changes

TRACON Pharmaceuticals announces $5M registered direct offering

TRACON Pharma launches $8.8M direct offering

TRACON Pharmaceuticals, Inc. Announces Dosing of First Patient in ENVASARC Pivotal Trial

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study